Clinical Change Order Evaluation and Vendor Negotiations

Change Order Negotiation
  • October 29, 2024

Client Challenge Faced

A small biopharma company was expecting a large Change Order (CO) from it’s primary CRO on a Phase IIB global clinical program that was experiencing delays. The company had limited means by which to evaluate the CO, given a mix of performance issues and COVID-related delays in study start-up and recruitment, as well as cost overruns due to low initial estimates for investigator pass-through grants. 

TriRadial Approach

  • The TriRadial team of experienced SMEs performed a deep-dive root-cause analysis into the patient recruitment delays and cost over runs
  • The team benchmarked investigator grants based on the site mix and our knowledge of current international rates in this therapeutic area
  • Performed a cost impact analysis of increases only, to facilitate a rapid negotiation approach
  • Revised the budgeting methodology used by the CRO to ensure transparency and to support negotiations
  • Helped client prepare for negotiation and participated in actual negotiation meetings with vendor

Results

  • Root cause analysis identified specific areas the needed to be addressed
  • Cost Impact Analysis enabled a timely review and immediately evident identification of cost changes and reconciliation
  • The team achieved a 33% reduction from originally proposed increases in Direct Fees
  • The client’s study and management team received firsthand experience leading contracting and vendor negotiation practices

 

LEAVE A COMMENT

More from the Blog

CTE 2021 Q&A

March 9, 2022
Raphaële Mary, one of TriRadial's Vendor Outsourcing Management experts, along with Alexandra Kemmer-Brück, Senior...

Part 3 of the series "CAPA for non-Quality Clinical folks"

May 11, 2021
This video podcast builds off of the second episode on the Corrective Action/Preventive Action (CAPA) process and...